Navigation Links
ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
Date:9/19/2012

BARCELONA, Spain, September 19, 2012 /PRNewswire/ --

ESTEVE's R & D team includes a total of 350 people, 13% of the total global workforce, with the capability to work in all areas of drug discovery and the development of new medicines. This new R&D Center will house 92 scientists focused on two key phases in drug development; (1) The discovery phase, the phase during which new chemical entities are identified that may have the ability to positively change the course of a disease and, (2) the preclinical development phase, which includes performing all the necessary tests to provide the appropriate evidence to allow a new drug to be evaluated in humans.

The transfer to the PCB is an example of ESTEVE's commitment to research, despite the difficult socio-economic environment, as a way to maintain long-term sustainability. One of the keys to this sustainability is the ability to provide innovative solutions to medical needs that have not yet been adequately met. In this new facility, the company expects to increase performance in its R & D activities, improving the overall productivity of the discovery process in the development of new drugs and shorten the time to market.

This is the first alliance of its kind, where a large pharmaceutical company will locate all key competence units for drug discovery and preclinical development in a top quality academic / scientific environment in Spain.

The decision-making process to transfer the R & D team to the PCB took into consideration several factors, the most notable of which is the excellent infrastructure, the advantages of working in a high quality scientific and technical environment and the presence, in a common area, of scholars, researchers, talented young people and groups of entrepreneurs. It represents a further step towards a single model of open innovation in pharmaceutical R & D. ESTEVE's key strategy in R & D is an active policy of creating strategic alliances with universities, public research centres, technology companies and other companies in the sector, both in Spain and abroad

For more information go to http://www.esteve.com/investigacion-desarrollo


'/>"/>
SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
4. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
5. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
11. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Valeritas Holdings, Inc. (OTCQB: VLRX) ... offering (APO). This was accomplished via a reverse merger ... a private placement of approximately 5 million shares of ... Under the terms of the reverse merger, which ... will trade on the OTC Markets under the symbol ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Ischemic Stroke ...  report to their offering.       ... Global Acute Ischemic Stroke Market and ... into Acute Ischemic Stroke pipeline products, Acute ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
Breaking Medicine Technology:
(Date:5/5/2016)... IN (PRWEB) , ... May 05, 2016 , ... ... benefits advisory organization, announces McLaughlin & Smoak Benefits as the latest addition to ... Smoak Benefits has a dedicated team of compliance, wellness, human resources, and health ...
(Date:5/5/2016)... ... May 05, 2016 , ... Michael ... charity program created to assist the people of their local community. The agency ... organizations and community leaders. Their hope is to bring awareness to important local ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... community enrichment program serving families of greater Dubuque, IA. The current campaign fundraises ... and honorably discharged veterans. Donations to Veteran’s Freedom Center may now be made ...
(Date:5/5/2016)... ... May 05, 2016 , ... TIME for Kids and The ZAC Foundation – ... partnership to reach nearly 1 million children with important water safety messages before summer ... leading cause of accidental death in children one to 6 years of age. ...
(Date:5/5/2016)... ... 05, 2016 , ... The 2016 Nike Soccer Camp will be directed by ... coaching staff. Together they bring their winning Vandals coaching philosophy to young athletes. Programs ... 5-13, and high school players. Session dates are as follows: , Youth Day Camp ...
Breaking Medicine News(10 mins):